SICS: effective solution to huge cataract problem

Article

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world.

Small incision cataract surgery (SICS) is a highly desirable and effective technique for India and other countries in the eastern hemisphere because it provides a highly effective and economic treatment for the vast cataract population in that part of the world, said Dr Satyajit Sinha of the AB Eye Institute, Patma, India.

"India's population has just topped 1 billion. There are 16 million cataract patients, and two million are added every year," said Dr Sinha. "But there are just 16,000 ophthalmologists, with 10,000 operating, which means there is a huge patient load for each doctor. We need a simple and effective way to combat cataract."

In this context, the choice of surgery must be weighed against the pressing need for treatment. Extra capsular cataract extraction (ECCE) has a short learning curve, SICS a longer one, but phaco requires a difficult and lengthy apprenticeship. Complications caused by 'in-training calamities' are worse with phaco, Dr Sinha noted.

SICS has a number of advantages. It means earlier rehab for patients than ECCE. There are no complications with sutures or suture removal. It has advantages over phaco for grade three, four and five cataracts. Patients are happy, too.

"One side of the globe is phaco. But on the other side of the globe, where cost is a big factor, we use SICS," he said. "Now high-quality, low-cost surgical instruments are being made indigenously by Indian companies. You can buy a crescent and keratome for $2. You can perform a SICS surgery and buy the IOL for $20 per patient. Phaco machines, by contrast, are expensive," said Dr Sinha.

As a result, India has the most SICS surgeons in the world, and highest number of SICS training centres.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.